Liver disease affects an estimated 1.5 billion people globally, with many cases undiagnosed until late stages. As liver conditions like metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) grow more common, early detection and proactive management have become essential in addressing this pressing health issue.

To support healthcare providers in this effort, Echosens has introduced the Liver Health Management (LHM) platform—a cloud-based solution designed to optimise liver disease care across various clinical settings.

The LHM platform integrates with Echosens' FibroScan® technology, enabling automated result transfers, enhanced exams through biological markers, and data-driven interpretation tools. This integration offers healthcare providers real-time insights, supporting more informed care decisions and improved patient outcomes.

The platform also features tools that streamline workflows, including synchronisation between FibroScan® devices and the platform, remote interpretation of results, and secure data storage, making liver disease management more efficient and comprehensive.

Through automated result transfers and accessible interpretation features, the LHM platform enables providers to identify at-risk patients more efficiently, helping to deliver timely interventions.

The platform aims to make liver screening routine and accessible, addressing the rising prevalence of MASLD and MASH by supporting early detection while the condition remains manageable.

With the increasing burden of liver disease and the availability of new treatment options like Madrigal Pharmaceuticals' Rezdiffra™, introduced earlier this year, the LHM platform offers critical support to clinicians. By facilitating earlier intervention, it provides a timely response to the escalating demand for liver care, giving patients a better chance at improved health outcomes.




Source: prnewswire.com

Report Abuse